Getting medicines to those who need them most

We recognize that the patients and families who battle life-threatening diseases anxiously await more effective medicines with each passing day. Knowing this drives us to work harder, to deliver transformative treatments more swiftly.

We also seek to ensure any medicine we develop is safe and effective and follows the rigorous guidelines established by regulatory agencies.

We strive to balance these two complementary and vital goals in all that we do.

To learn more about our clinical trials, visit blueprintclinicaltrials.com or contact our study director at studydirector@blueprintmedicines.com or (617) 714-6707.

Our clinical trials

Our clinical trials in

Gastrointestinal stromal tumors (GIST)

Trial Phase

Trial Phase 1

Target Population

Target Population

Advanced GIST

Study Status

Study Status

Active, fully enrolled

ClinicalTrials.gov
Study Number

Study Number

NCT02508532

Trial Phase

Trial Phase 3

Target Population

Target Population

Third-line or fourth-line GIST

Study Status

Study Status

Active, target enrollment achieved

ClinicalTrials.gov
Study Number

Study Number

NCT03465722

Our clinical trials in

Systemic mastocytosis (SM)

Trial Phase

Trial Phase 1

Target Population

Target Population

Aggressive SM, SM with an associated hematologic neoplasm, and mast cell leukemia

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT02561988

Trial Phase

Trial Phase 2

Target Population

Target Population

Aggressive SM, SM with an associated hematologic neoplasm, and mast cell leukemia

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT03580655

Trial Phase

Trial Phase 2

Target Population

Target Population

Indolent SM and smoldering SM

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT03731260

Our clinical trials in

RET-altered cancers

Trial Phase

Trial Phase 1/2

Target Population

Target Population

RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) or other solid tumors with a RET fusion or mutation

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT03037385

Our clinical trials in

Hepatocellular carcinoma (HCC)

Trial Phase

Trial Phase 1

Target Population

Target Population

FGFR4-activated HCC, defined as overexpression of FGF19 assessed by an immunohistochemistry test

Study Status

Study Status

Active, recruiting

ClinicalTrials.gov
Study Number

Study Number

NCT02508467